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Conclusion Patients with CKD often take NSAIDs. This 
applies especially to the group of people undergoing hemo-
dialysis, which is mainly associated with chronic osteo-
articular pain. The results also show a low awareness of 
painkillers’ adverse effects.
Keywords Chronic kidney disease · NSAIDs · Pain · 
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Introduction
Almost 40 % of patients visit primary care providers due to 
mild to moderate acute pain [1]. Moreover, about 70 % of 
emergency departments’ interventions are associated with 
pain complaints [2]. In Poland, 24 % of the general popula-
tion, in the case of discomfort or pain, prefer self-treatment 
using pharmaceuticals, including non-steroid anti-inflam-
matory drugs (NSAIDs), to the doctor’s advice [2]. NSAIDs 
are mostly available in Poland without prescription (over 
the counter, OTC). Reports show also that Poland is in the 
6th position in Europe in terms of OTC sales of painkillers 
[3].
NSAIDs are the cornerstone of pain management in 
patients who have inflammatory pain, acute pain (e.g. 
headache, postoperative pain, and orthopedic fractures) or 
chronic pain (e.g. rheumatoid arthritis, osteoarthritis, and 
gout) [4]. Approximately 70 % of people aged over 65 years 
use NSAIDs at least once a week, and half of them take at 
least 7 doses per week. Both traditional NSAIDs, and the 
second generation cyclooxygenase-2 inhibitors offer supe-
rior efficacy compared with acetaminophen, but they also 
carry a significant risk for serious gastrointestinal, cardio-
vascular and renal adverse events [5, 6]. NSAIDs use has 
been associated with both acute kidney injury in the general 
Abstract
Aims Nonsteroidal anti-inflammatory drugs (NSAIDs) are 
the cornerstone of pain management. There are no detailed 
data on NSAIDs use in Poland, especially in patients with 
chronic kidney disease (CKD). The aim of this study was 
to evaluate the frequency, circumstances, and causes of 
NSAIDs use as well as knowledge of their side-effects in 
patients with CKD.
Method This cross-sectional study was conducted in 972 
individuals with CKD, enrolled in a written survey origi-
nally developed by the authors. There were 574 patients 
with CKD stage I-IV, 414 patients after renal transplantation 
stage II-IV (CKDT) and 84 dialyzed patients (44 peritoneal, 
40 hemodialysis).
Results Among the entire study group, 16.9 % of patients 
used NSAIDs every day, or several times a week. The aver-
age number of tablets taken within a month was 21.8. Sub-
group analysis revealed that NSAIDs were taken most often 
by patients on hemodialysis: 35 % of them used NSAIDs 
every day or several times a week (43.15 pills per month). 
The most common reason for using NSAIDs were bone-
joint pain (29.3 %) and headache (26.2 %). Side effects of 
painkillers such as renal function deterioration and the pos-
sible promotion of stomach ulcers were experienced by 43.6 
and 37.6 % of respondents, respectively.
1 3
2 J Nephrol
population, and occurred in 79, 27.4 and 21.5 % respec-
tively. Detailed characteristics of the group are presented in 
Tables 1 and 2. Hemodialysis patients were the oldest com-
pared to the other subgroups (ANOVA: p < 0.001).
NSAIDs use
Among the entire study group, as many as 6.58 % of patients 
used NSAIDs every day, 10.3 % a few times a week, and 
13.8 % a few times a month; 35.7 % of them took NSAIDs 
occasionally, i.e. a few times a year, while 33.5 % reported not 
to use NSAIDs. The median number of tablets taken within 
a month, in persons using NSAIDs regularly, i.e. every day 
or a few times a week, was 20. Use of two NSAIDs at the 
same time was reported by 13 % of respondents. The most 
common reasons for using NSAIDs were bone-joint pain 
(29.3 %), and headache (26.2 %) (Table 3). The decision 
about taking NSAIDs was made in 46.71 % of cases by the 
patients themselves, in 43.41 % by the doctor, and in 9.88 % 
by a pharmacist. Subgroup analyses revealed that NSAIDs 
were taken most often by hemodialysis patients: 17.5 % of 
them took pills every day, and 17.5 % used NSAIDs a few 
times a week (Fig. 1). The median number of NSAIDs taken 
population, and chronic kidney disease (CKD) progression 
in those with chronic nephropathies [7]. In addition, NSAIDs 
interact unfavorably with some commonly prescribed medi-
cations in CKD patients, including loop diuretics, angioten-
sin-converting enzyme inhibitors, and angiotensin receptor 
blockers, leading to their reduced effectiveness along with 
an increased risk of renal impairment [8].
Despite these potential adverse effects of NSAIDs in 
CKD patients, little is known about the patterns of NSAIDs 
use in this population. The aim o  this s udy was evaluate 
the frequency, circumstances, and causes of NSAIDs’ use, 
as well as knowledge of their side-effects in patients with 
CKD.
Materials and Methods
A cross-sectional survey study was conducted in the first 
6 months of 2014 in patients with CKD who were under 
the care of the Department of Nephrology, Medical Univer-
sity of Gdansk, Poland. This survey was offered to all 1,300 
patients who were under the care of the local Outpatient 
Unit, and the Hemodialysis and Peritoneal Dialysis Units. 
The written survey was originally developed by the authors. 
It consisted of 22 questions. Aspirin used in small doses 
(i.e. 75 mg) was excluded from our primary definitions of 
NSAIDs because of its relatively low adverse effects rate, 
and because its use is commonly recommended for the pre-
vention of comorbid cardiovascular complications. To any-
one having difficulty completing the written survey, support 
was given from students of the Medical Faculty, Medical 
University of Gdansk.
Data was evaluated using a STATISTICA (version 12.0 
Stat Soft Inc.) software package. The results are presented 
as mean value ± standard deviation (SD), median, interquar-
tile range and numbers or percent frequency, as appropri-
ate. The quantitative variable differences were assessed by 
analysis of variance (ANOVA) or the non-parametric Krus-
kal–Wallis test. In order to measure the differences in preva-
lence between selected categories, we used the Chi square 
(χ2) test for the contingency tables. A p < 0.05 (two-tailed) 
was considered statistically significant.
Results
A total of 972 individuals (74.8 %) responded to the survey. 
There were 574 patients with CKD stage I-IV (all patients 
with CKD stage V were under renal replacement therapy), 
314 patients after kidney transplantation (CKDT), and 84 
dialyzed patients: 44 peritoneal (PD) and 40 hemodialysis 
(HD). Hypertension, cardiovascular and bone-joint dis-
eases were the most frequent comorbidities of our study 
Table 1 Characteristics of the study population
Number of patients 972
M 464 (47.7 %)
CKD 1–4 574 (59.1 %)
Peritoneal dialysis 44 (4.5 %)
Hemodialysis 40 (4.1 %)
Kidney transplantation 314 (32.3 %)
Age (years)
Average ± SD 55.0 ± 17.5
Duration of CKD from diagnosis (years)
Median and IQR 10; 5–20
BMI (kg/m2)
Average ± SD 26.3 ± 5.0
Education
Basic/technical 290 (29.8 %)
Secondary 420 (43.2 %)
Higher 262 (27.0 %)
Other diseases
Hypertension 768 (79.0 %)
Diabetes 226 (23.2 %)
Cardiovascular disease 266 (27.4 %)
Cancer 78 (8.0 %)
Bone and joint disease 209 (21.5 %)
Average number of drugs
Median and IQR 5.5; 3.0–8.0
IQR interquartile range, SD standard deviation, BMI body mass 
index, CKD chronic k dney disease
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of blood pressure control were known by 43.6, 37.6 and 
18.2 % of respondents, respectively. The patients who 
themselves decided to use NSAIDs derived their knowl-
edge about these drugs from the media (72.5 %), friends 
(15.0%) and pharmacists (12.5 %). Subgroup analysis 
revealed that knowledge about potential deterioration of 
renal function by NSAIDs was greatest among PD patients 
(χ2 test: p < 0.01), while knowledge about promotion of 
stomach ulcers was greatest among HD patients (χ2 test: 
p < 0.05) (Fig. 3).
within a month in the hemodialysi  and pe itoneal di lysis 
patients who used NSAIDs regularly, i.e. every day or a few 
times a week, was 30 and 32.5 tablets, respectively (Fig. 2).
Side-effects knowledge
As many as 54.1 % of the respondents using NSAIDs did 
not take into account their side-effects. The most common 
side-effects of NSAIDs such as a possible deterioration of 
renal function, peptic ulcer disease (PUD), and impairment 
Fig. 1 The frequency of use of 
NSAIDs in subgroups. *χ2 test 
p < 0.01 (difference between 
study subgroups: CKD 1–4 vs. 
CKDT vs. HD vs. PD). **χ2 test 
p < 0.001 (difference between 
study subgroups: CKD 1–4 vs. 
CKDT vs. HD vs. PD)
 







Average* ± SD 57.2 ± 19.4 50.1 ± 13.6 61.3 ± 11.1 55.9 ± 14.5
Gender M/F 292/282 178/136 17/23 21/23
BMI (kg/m2)
Average ± SD 26.8 ± 5.4 25.6 ± 4.1 24.1 ± 3.8 26.1 ± 4.4
Duration of CKD from diagnosis (years)
Median and IQR 7.0; 3.0–15.0 15.0; 10.0–22.0 14.0; 7.0–28.0 5.0; 3.0-14.5
Bone-joint disease, n (%)** 153 (27.5) 42 (13.4) 21 (52.5) 2 (4.5)
Cancer, n (%)** 60 (10.4) 13 (4.1) 1 (2.5) 4 (9.1)
Diabetes, n (%)** 135 (23.5) 70 (22.3) 10 (25.0) 11 (25.0)
Hypertension, n (%)** 432 (75.1) 267 (85.0) 30 (75.0) 40 (91.0)
Cardiovascular disease, n (%)** 175 (30.5) 59 (18.8) 18 (45.0) 14 (31.8)
IQR interquartile range, CKD chronic kidney disease
*ANOVA p < 0.001 (difference between study subgroups: CKD 1–4 vs. CKDT vs. HD vs. PD)
**χ2 test p < 0.001 (difference between study subgroups: CKD 1–4 vs. CKDT vs. HD vs. PD)





CKD patients seem to be particularly vulnerable to the 
occurrence of the side-effects of NSAIDs, in particular, to 
the adverse effects of NSAIDs on blood pressure control, 
decreased renal blood flow, and promotion of PUD [7]. The 
prevalence of hypertension may be as high as 90 % in the 
CKD population. Through a variety of mechanisms related 
to prostaglandin inhibition, including sodium retention and 
vasoconstriction, NSAIDs may increase blood pressure. 
NSAIDs have been shown to produce a clinically significant 
increment in mean blood pressure by 5 mmHg, most marked 
in patients with controlled hypertension [9]. The incidence 
of PUD in patients with CKD is 10 to 12 times higher than 
in patients without CKD. In particular, PUD affects chroni-
cally hemodialyzed persons. One of the most important risk 
factors for the development of PUD and its complications is 
the use of NSAIDs [9]. NSAIDs use is also associated with 
a threefold greater risk for acute renal failure compared to 
non-NSAIDs use, after adjusting for age, sex, body mass 
index, and several comorbidities [6]. In addition, NSAIDs 
may cause deterioration in renal function in patients with 
CKD especially in those treated with renin angiotensin sys-
tem blockers, or with episodes of hypotension [10, 11]. Thi
may be particularly dangerous for renal transplant recipi-
ents, or patients with stage CKD II-IV. Given all these facts, 
it is not surprising that knowledge concerning the use of 
NSAIDs in CKD patients is of great importance.
The study showed that approximately 17 % of patients 
with CKD, and more than one-third of the HD patients, use 
NSAIDs daily or several times a week. Among them, up to 
13 % of patients reported using two different drugs at the 
Table 3 Causes of use of NSAIDs (%)





Abdominal pain 7.7 5.2 7.1 10.3 11.1
Headache 26.2 22.4 34.7 31.0 29.6
Menstrual cramp6.9 6.8 2.9 2.0 3.7
Bone and joint pain 29.3 25.6 19.7 69.0 33.3
Inflammation 15.5 12.1 18.2 15.4 22.2
Other 14.4 14.1 11.8 16.3 13.2
CKD chronic kidney disease, CKDT chronic kidney disease after 
kidney transplantation, HD hemodialysis, PD peritoneal dialysis
Fig. 3 The knowledge of the 
adverse effects of analgesics 
in subgroups. *χ2 test p < 0.01 
(difference between study sub-
groups: CKD 1–4 vs. CKDT vs. 
HD vs. PD). **χ2 test p < 0.001 
(difference between study sub-
groups: CKD 1–4 vs. CKDT vs. 
HD vs. PD)
 
Fig. 2 The median and I, II quartyl of the number of NSAIDs tablets 
taken per month by patients who used NSAIDs regularly i.e. every day 




It may indicate that bone-disease problems are a very impor-
tant, and still unsolved, issue. Of great concern, awareness 
about the risks arising from the use of NSAIDs is particu-
larly poor in patients after renal transplantation. Only 19 and 
40 % of them were aware that use of NSAIDs could lead to 
a possible deterioration of blood pressure control or of graft 
function, respectively. Given these facts, specific education 
is urgently required in this population. Intervention strategies 
to improve the prescribing pattern in CKD patients should be 
also targeted to GPs and pharmacists, who often recommend 
NSAIDs in this specific population [14].
Conclusions
Patients with CKD quite often take NSAIDs. This applies 
especially to patients undergoing hemodialysis, where 
NSAID use is mainly associated with their chronic osteo-
articular complaints. In addition, our findings show a low 
awareness of the adverse side-effects NSIADs, which is 
especially alarming in patients after renal transplantation.
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